Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.

Name: Αlpha¹ Rigor Record — Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
Item: Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
Rating: 90
Author: Αlpha¹

Malhotra A, Grunstein R, Azarbarzin A, Sands S, Somers VK, Aronne LJ, Jastreboff AM, Lou J, Chakladar S, Dunn JP, Bunck MC, Bednarik J

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 3 high issues for “Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced4 types

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Study-design details incomplete (controls, blinding, power)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper reports secondary analyses of two well-conducted randomized trials, with generally rigorous methods and transparent reporting. However, several reporting gaps are present: the randomization method and power analysis are not described, inclusion/exclusion criteria are only referenced, p-values are often reported as thresholds, and the ethics board is not named in the main text. These are fixable reporting issues rather than fundamental methodological flaws, but they reduce the paper's standalone completeness.

This assessment is based on three independent reviews of the same paper, with the copyedit pass and verification components (citation, statistics, reproducibility, preregistration, claim audit) integrated. The reviewers diverged on study design (pass vs. warn), ethical approvals (pass vs. warn), and statistical analysis (pass vs. warn); the synthesized judgments reflect the preponderance of evidence. The statistics verification covered only 5 recomputable tests; all were consistent, but most p-values could not be independently verified. No retracted or unfound references were identified.

12 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites relevant literature on OSA-related cardiovascular risk, the limitations of PAP therapy, the role of obesity, and the effects of tirzepatide on weight and glucose control. It then formulates a clear hypothesis and addresses limitations of prior research such as the lack of consistent cardiovascular benefits with PAP. All three sub-criteria are adequately reported.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific premise by citing prior work on OSA, obesity, PAP therapy, and tirzepatide, and provides a logical rationale for the hypothesis that tirzepatide improves cardiometabolic risk.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Obstructive sleep apnea (OSA) is a common disorder with major cardiometabolic and neurocognitive sequelae. Excess adiposity is a major reversible etiologic risk factor for OSA and its complications. Nasal continuous positive airway pressure (PAP) to this point has been first line therapy for OSA but is not always well tolerated. Moreover, PAP has not shown consistent benefits in patients with OSA from the perspective of cardiovascular outcomes.”

direct quote[Introduction, paragraph 5]

“Based on this conceptual framework and including a complete set of study prespecified cardiometabolic endpoints, we sought to test the hypothesis that tirzepatide treatment in the SURMOUNT-OSA studies would yield improvement in cardiometabolic risk measures as compared to placebo.”